{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:30:12Z","timestamp":1782311412934,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00715-4","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:12:42Z","timestamp":1756368762000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct03668613","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kulli","family":"Kingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philemon","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Lazareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n Vicente","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirina","family":"Bartonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Ballona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"O\u2019Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"1","key":"715_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161\u2013201.","journal-title":"J Am Acad Dermatol"},{"key":"715_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PHMT.S75834","volume":"7","author":"J Thomas","year":"2016","unstructured":"Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatr Health Med Ther. 2016;7:25\u201338.","journal-title":"Pediatr Health Med Ther"},{"key":"715_CR3","first-page":"121","volume":"6","author":"R Pinson","year":"2016","unstructured":"Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121\u20139.","journal-title":"Psoriasis (Auckl)"},{"issue":"Suppl 1","key":"715_CR4","first-page":"S71","volume":"12","author":"BK Katakam","year":"2021","unstructured":"Katakam BK, Munisamy M, Rao TN, Chiramel MJ, Panda M, Gupta S, et al. Recommendations for management of childhood psoriasis. Indian Dermatol Online J. 2021;12(Suppl 1):S71-s85.","journal-title":"Indian Dermatol Online J"},{"issue":"7","key":"715_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","volume":"153","author":"E Osier","year":"2017","unstructured":"Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017;153(7):698\u2013704.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"715_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pedhc.2020.12.006","volume":"35","author":"BY Kang","year":"2021","unstructured":"Kang BY, O\u2019Haver J, Andrews ID. Pediatric psoriasis comorbidities: screening recommendations for the primary care provider. J Pediatr Health Care. 2021;35(3):337\u201350.","journal-title":"J Pediatr Health Care"},{"issue":"5","key":"715_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373\u201384.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"715_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2019.4835","volume":"156","author":"I Bronckers","year":"2020","unstructured":"Bronckers I, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384\u201392.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"715_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ijwd.2020.09.012","volume":"7","author":"Y Goenaga-V\u00e1zquez","year":"2021","unstructured":"Goenaga-V\u00e1zquez Y, Lauck KC, Hebert AA. Therapeutic challenges in managing pediatric psoriasis. Int J Womens Dermatol. 2021;7(3):314\u20138.","journal-title":"Int J Womens Dermatol."},{"issue":"8","key":"715_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","volume":"12","author":"K Peris","year":"2022","unstructured":"Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753\u201375.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"715_CR11","unstructured":"Cosentyx [summary of product characteristics]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2023."},{"key":"715_CR12","unstructured":"COSENTYX [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2023."},{"key":"715_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/PPA.S350753","volume":"17","author":"J Narbutt","year":"2023","unstructured":"Narbutt J, Nied\u017awied\u017a M, Lesiak A, Ceryn J, Skibi\u0144ska M. Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability. Patient Prefer Adherence. 2023;17:421\u201331.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"715_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40272-022-00507-0","volume":"24","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 2022;24(4):377\u201387.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"715_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","volume":"86","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"715_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.847308","volume":"13","author":"V Di Lernia","year":"2022","unstructured":"Di Lernia V, Macca L, Peterle L, Ingrasciotta Y, Trifir\u00f2 G, Guarneri C. Efficacy of systemic biologic drugs in pediatric psoriasis: evidence from five selected randomized clinical trials. Front Pharmacol. 2022;13: 847308.","journal-title":"Front Pharmacol"},{"issue":"4","key":"715_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/1346-8138.16702","volume":"50","author":"WM Wang","year":"2023","unstructured":"Wang WM, Jin HZ. Biologics in pediatric psoriasis. J Dermatol. 2023;50(4):415\u201321.","journal-title":"J Dermatol"},{"key":"715_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19063","author":"D Krasowska","year":"2023","unstructured":"Krasowska D, Gambichler T, Cort\u00e9s C, Horev A, Compagno N, Dahale SS, et al. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19063.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"715_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2022","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2022;188(2):198\u2013207.","journal-title":"Br J Dermatol"},{"issue":"9","key":"715_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"715_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ajd.13893","volume":"63","author":"P Foley","year":"2022","unstructured":"Foley P, Spelman L, Murrell DF, Mate E, Tronnberg R, Lowe PM. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: results from the HOPE study. Australas J Dermatol. 2022;63(3):312\u201320.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"715_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jdv.16632","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35(2):431\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"715_CR23","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102: adv00698.","journal-title":"Acta Derm Venereol"},{"key":"715_CR24","unstructured":"EMA (2012) Ethical considerations for pediatric trials. https:\/\/www.ema.europa.eu\/en\/documents\/report\/ethical-considerations-paediatrictrials_en.pdf. Accessed 29 Oct 2020."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00715-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:11Z","timestamp":1760714951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00715-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00715-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"30 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novartis Pharma AG, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kulli Kingo has received fees for serving as an investigator in studies sponsored by AbbVie, Celgene, Galderma, Merck, Mitsubishi Tanabe Pharma, Novartis, Regeneron Pharmaceuticals, and Sandoz. Stefan Beissert has been on the advisory board of AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Deutschland GmbH, Amgen GmbH, Celgene GmbH, Galderma Laboratorium GmbH, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, MSD SHARP & DOHME GmbH, Menlo Therapeutics, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH, and UCB Pharma GmbH and received speaker honorarium from Novartis Pharma GmbH, AbbVie Deutschland GmbH & Co. KG, MSD SHARP & DOHME GMBH, Pfizer Pharma GmbH,\u00a0Janssen-Cilag GmbH, Galderma Laboratorium GmbH, Celgene GmbH, La Roche-Posay Laboratoire Pharmaceutique, Actelion Pharmaceuticals Deutschland GmbH, GlaxoSmithKline GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Sanofi-Aventis Deutschland GmbH, Almirall Hermal GmbH, and Sandoz\/Hexal\u00a0AG. Svetlana Lazareva and Jirina Bartonova declare no conflicts of interest. Asunci\u00f3n Vicente Villa has been an investigator in studies, advisor, speaker, and\/or consultant for AbbVie, Almirall, Amgen, Amryt, Boehringer Ingelheim, Bristol Myers Squibb, Ferrer, Galderma, Jansen, LEO Pharma, Lilly, Novartis, Pierre Fabre, Pfizer, and Sanofi-Genzyme. Rosalia Ballona has received fees for serving as an investigator in this study sponsored by Novartis. Nina Magnolo has been an advisor, speaker, and\/or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, La Roche-Posay, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Dr. Wolff, Sanofi, and UCB Pharma. Amita Bansal, Ruvie Martin, Heng Fan, Charles O\u2019Doherty, and Philemon Papanastasiou are employees and shareholders of Novartis. Shoba Ravichandran was a full-time employee at the time the research was conducted and is a current stockholder of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available. Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. These requests are reviewed and approved on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and in compliance with all national, federal, local, or regional requirements. The institutional review board\/ethics committee of each participating center approved the study protocol.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A parent or legal guardian provided written informed consent, and the patient provided written assent, at screening before any assessment was performed. If patients reached age of consent (as per local law) during the study, they needed to also sign the corresponding study informed consent(s).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Written informed consent was obtained from each patient or legal representative of the patient for anonymized patient information to be published.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors were involved in the drafting and critical review of the manuscript and approved the final version for submission. K.K., S.B., S.L., A.V.V., J.B., R.B., and N.M. contributed to the design of the study and were involved in the acquisition of clinical data and participated as principal investigators in the clinical study from which data are reported in the manuscript. P.P., A.B., R.M., H.F., C.O.D., and S.R. were involved in the conception, design, and clinical conduct of the trial. R.M. and H.F. were involved in the analysis of the data in the manuscript. All authors were involved in the interpretation of data in the manuscript. All authors agreed to be accountable for all aspects of the work and attest to the accuracy and integrity of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}